Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cheap rectal pill cut C-Section bleeding?

NCT ID NCT07188207

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether giving a rectal dose of misoprostol before a planned C-section, on top of the usual oxytocin, can reduce blood loss during and after surgery. About 282 women having elective C-sections will be randomly assigned to receive either standard care or standard care plus misoprostol. The goal is to find a simple, low-cost way to prevent dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
misoprostol (rectal) plus oxytocin (intravenous)
What this could lead to
If it works, this could offer a cheap, heat-stable way to lower the risk of dangerous bleeding during planned C-sections.
What could go wrong
This is a small, early-stage trial (282 participants) and the added benefit over standard care may be small. Misoprostol can cause side effects like shivering or fever.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 282 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-45 years. * Singleton pregnancy at ≥37 weeks of gestation. * Elective cesarean section planned under spinal anesthesia. * Hemodynamically stable prior to surgery. * Provided written informed consent. Exclusion Criteria: * Multiple pregnancy. * Antepartum hemorrhage (e.g., placenta previa, abruption). * Coagulopathy, thrombocytopenia, or anticoagulant therapy. * Severe medical comorbidities (e.g., uncontrolled hypertension, cardiac disease, hepatic or renal impairment). * Known allergy or contraindication to prostaglandins or oxytocin. * Intrauterine fetal death or major fetal anomaly. * Refusal to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postpartum hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.